Aviva Systems Biology's founding team has extensive backgrounds in biotechnology development and commercialization. Since 2002, they have guided Aviva into becoming one of the premier antibody manufacturing organizations in its respective industry.
Peter Jiang, M.D. - Chief Executive Officer
Dr. Jiang brings a vast amount of knowledge and experience in biotechnology and management to Aviva from more than fifteen years of experience in the pharmaceutical and biotech industries. Dr. Jiang has previously served as Vice President of Operations in Aviva in San Diego and President of Aviva in Beijing. Before joining Aviva, Dr. Jiang managed Tang Pharmaceuticals in China as General Manager from 1999 to 2007. Prior to that, Dr. Jiang served as assistant professor in the Department of Medicine at Northwestern University. Dr. Jiang holds a M.D. degree in Pediatrics.
Kevin J. Harvey, Ph.D. - President
Dr. Harvey is responsible for leading all Aviva Systems Biology and Genway Biotech operations with a focus on delivering profitable growth initiatives across the Company. He brings over 18 years of biotechnology experience and a proven track record of delivering profitable growth within the antibody product segments. Most recently Dr. Harvey has served as General Manager of Thermo Fisher Scientific’s antibody business where he had financial and product development responsibility for the business segment. He has held numerous leadership roles at Affymetrix (acquired by Thermo Fisher Scientific) and EMD Millipore Inc. (Merck KGaA), where he was responsible for research and development, product management, business development, and commercial strategy. Dr. Harvey has a Ph.D. in Microbiology and Immunology from the University of Illinois of Chicago and held a Postdoctoral Fellowship at the University of California, San Diego.
Husheng Zhang, Ph.D. - Vice President of Aviva Systems Biology Beijing
Dr. Zhang is responsible for polyclonal antibody production, quality control, technical support and R&D in Aviva Systems Biology Beijing. He has over seven years of molecular biology experience and polyclonal antibody production experience. He is a graduate of the prestigious Cancer Institute, Chinese Academy of Medical Sciences.